Jones Lang LaSalle has released its 2011 Global Life Sciences Cluster Report. The Denver Market ranks 12th overall in the U.S. and is considered an emerging market.
According to the report overview:
"As life science companies determine which aspects of the business are vital to drug discovery and innovation, they are bifurcating their location strategies to optimize the cost versus output equation.
Established clusters within the United States and Europe remain destinations of choice for core aspects of drug discovery. Companies are able to offset the high costs of operating in established clusters with the increased odds of innovation due to deep, rich talent pools and infrastructure. Emerging global clusters, however, offer cost-advantageous manufacturing sites that provide both revenue and margin opportunities. Additionally, emerging clusters are becoming more competitive in hightech aspects of the value chain, due to significant capital investments
and improved political policies."
Link to the report pdf